Key facts
- Prime Radiant Partners is investing $50 million in Cellares.
- Cellares develops high-tech robots for mass-producing cancer treatments.
- The company is raising funds in anticipation of a potential IPO in 2027.
Prime Radiant Partners, an upstart private equity firm, is injecting $50 million into Cellares. Cellares is a biotechnology company focused on creating high-tech robots designed for the mass production of cancer treatments. This funding round is occurring as Cellares gears up for a potential initial public offering, which is anticipated in 2027.